356:
study called PEARL-SC to investigate the efficacy, safety, and tolerability of blisibimod in subjects with systemic lupus erythematosus. The PEARL-SC study, completed in April 2012, yielded data that has been published. Blisibimod is currently being tested in a Phase 3 study, CHABLIS-SC1, for
925:
Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, et al. (September 2015). "A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study".
332:, thus decreasing B-cell survival and proliferation throughout the body. Improvements in disease activity have been observed in patients with systemic lupus erythematosus and rheumatoid arthritis following treatment with BAFF inhibitors in clinical trials.
804:
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. (February 2011). "Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial".
484:
Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. (August 2008). "Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus".
413:"Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS)"
1202:
986:
40:
221:
769:
Fabris M, Grimaldi F, Villalta D, Picierno A, Fabro C, Bolzan M, et al. (January 2010). "BLyS and April serum levels in patients with autoimmune thyroid diseases".
1218:
1680:
1146:
1268:
717:"Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma"
1700:
1328:
979:
849:
1671:
1660:
1636:
1126:
2055:
912:
for "PEARL-SC Trial: A Study of the
Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus" at
1015:
1162:
972:
882:
412:
1294:
1026:
1980:
883:"Anthera Pharmaceuticals acquires the worldwide rights to a BAFF inhibitor for the treatment of lupus and other autoimmune diseases"
61:
550:
533:
1691:
1393:
282:
850:"Effects on B cells, safety, and efficacy of LY2127399, a novel anti-BAFF MAB, in patients with active rheumatoid arthritis"
668:"BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma"
2060:
1995:
258:
118:
384:
296:
survival, activation, and differentiation. Elevated levels of BAFF have been associated with several B-cell mediated
1985:
1627:
321:
1586:
1056:
441:
Browning JL (July 2006). "B cells move to centre stage: novel opportunities for autoimmune disease treatment".
250:
1339:
1035:
861:
329:
254:
1051:
1724:
534:"Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases"
1536:
1531:
1482:
1121:
1136:
1651:
1487:
1192:
1086:
617:
Neusser MA, Lindenmeyer MT, Edenhofer I, Gaiser S, Kretzler M, Regele H, et al. (January 2011).
305:
1894:
352:
treatments. It was subsequently acquired by
Anthera Pharmaceuticals, who in 2010 initiated a global
1602:
1492:
1384:
1101:
1096:
1091:
1081:
666:
Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, et al. (January 2005).
313:
297:
82:
1355:
1213:
1182:
848:
Genovese M, Bojin S, Biagini M, Mociran E, Cristei D, Georgescu L, Sloan-Lancaster J (June 2010).
1516:
1511:
1477:
1472:
1418:
1233:
1006:
998:
951:
913:
886:
830:
648:
466:
416:
309:
2005:
1309:
1299:
1289:
1223:
1172:
317:
1934:
1924:
1914:
1851:
1576:
1279:
1944:
1929:
1846:
1811:
1556:
1061:
995:
943:
822:
786:
748:
697:
640:
599:
555:
511:
458:
1871:
1046:
91:
1597:
1526:
1521:
1409:
1066:
935:
814:
778:
738:
728:
687:
679:
630:
589:
545:
501:
493:
450:
325:
163:
1505:
127:
1975:
1952:
1497:
1414:
1177:
715:
Quartuccio L, Fabris M, Moretti M, Barone F, Bombardieri M, Rupolo M, et al. (2008).
576:
Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, et al. (January 2001).
358:
301:
274:
1836:
1826:
1753:
1370:
1360:
1284:
1116:
743:
716:
692:
667:
353:
345:
270:
818:
2049:
1404:
1187:
1106:
955:
939:
834:
652:
2010:
1990:
1909:
1899:
1841:
1788:
1718:
1617:
1561:
1248:
1238:
1228:
1131:
1111:
1076:
1071:
470:
908:
578:"Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus"
782:
2020:
2015:
1919:
1904:
1876:
1866:
1861:
1816:
1783:
1778:
1773:
1768:
1763:
1748:
1743:
1566:
1551:
1546:
1365:
1350:
1167:
733:
964:
635:
618:
1856:
1758:
1612:
1157:
278:
202:
102:
594:
577:
2030:
2025:
1806:
1253:
388:
947:
826:
790:
752:
701:
644:
619:"Intrarenal production of B-cell survival factors in human lupus nephritis"
603:
559:
515:
462:
415:(Press release). Anthera Pharmaceuticals, Inc. 29 July 2010. Archived from
20:
253:(BAFF, also known as B-lymphocyte stimulator or BLyS), being developed by
1258:
885:(Press release). Anthera Pharmaceuticals, Inc. 2008-01-08. Archived from
683:
506:
286:
349:
497:
1831:
1821:
1466:
1462:
1458:
1454:
1450:
1446:
551:
10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S
293:
454:
147:
1501:
1442:
1438:
1434:
1430:
1426:
1422:
1319:
357:
systemic lupus erythematosus, and a Phase 2 study, BRIGHT-SC, for
348:
trials demonstrating comparable safety between the blisibimod and
341:
261:. It is currently under active investigation in clinical trials.
1886:
1798:
1735:
138:
968:
1127:
Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)
532:
Cheema GS, Roschke V, Hilbert DM, Stohl W (June 2001).
228:
1965:
1943:
1885:
1797:
1734:
1717:
1710:
1690:
1670:
1650:
1626:
1585:
1392:
1383:
1338:
1318:
1267:
1201:
1145:
1034:
1025:
1005:
201:
162:
157:
137:
117:
101:
81:
76:
60:
55:
39:
31:
26:
385:"A-623: BAFF Peptibody for the Treatment of Lupus"
1219:Granulocyte macrophage colony-stimulating factor
90:
387:. Anthera Pharmaceuticals, Inc. Archived from
980:
8:
19:
1986:Leukemia/leukocyte inhibitory factor (LIF)
1731:
1714:
1389:
1031:
987:
973:
965:
300:, including systemic lupus erythematosus,
1981:FMS-like tyrosine kinase 3 ligand (FLT3L)
1410:Interferon alpha (interferon alfa, IFN-α)
742:
732:
691:
634:
593:
549:
505:
126:
2003:Additional cytokine receptor modulators:
436:
434:
369:
1827:Cucurbitacin I (elatericin B, JSI-124)
764:
762:
527:
525:
340:Blisibimod was initially developed by
18:
1163:Granulocyte colony-stimulating factor
571:
569:
407:
405:
379:
377:
375:
373:
7:
1522:Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)
1295:Macrophage colony-stimulating factor
672:The Journal of Experimental Medicine
1996:Thymic stromal lymphopoietin (TSLP)
146:
14:
928:Annals of the Rheumatic Diseases
854:Annals of the Rheumatic Diseases
180:
174:
1527:Interferon omega (IFN-ω, IFNW1)
940:10.1136/annrheumdis-2013-205144
324:. Blisibimod binds to BAFF and
249:) is a selective antagonist of
2056:Drugs not assigned an ATC code
443:Nature Reviews. Drug Discovery
283:fragment crystallizable region
192:
186:
168:
1:
819:10.1016/S0140-6736(10)61354-2
721:The Open Rheumatology Journal
860:(Suppl3): 69. Archived from
783:10.1016/j.autrev.2009.07.005
259:systemic lupus erythematosus
1371:Thrombopoietin (THPO, MGDF)
1137:Pegol sihematide (EPO-018B)
1057:Carbamylated erythropoietin
734:10.2174/1874312900802010038
2077:
636:10.1038/modpathol.2010.184
158:Chemical and physical data
1920:Tofacitinib (tasocitinib)
1877:Tofacitinib (tasocitinib)
1784:Tofacitinib (tasocitinib)
218:
1598:Interferon gamma (IFN-γ)
595:10.4049/jimmunol.166.1.6
538:Arthritis and Rheumatism
486:Arthritis and Rheumatism
273:consisting of four BAFF
251:B-cell activating factor
1498:Interferon beta (IFN-β)
322:Hashimoto's thyroiditis
255:Anthera Pharmaceuticals
1976:Cardiotrophin 1 (CT-1)
906:Clinical trial number
328:interaction with BAFF
1973:Additional cytokines:
1900:Decernotinib (VX-509)
1537:Peginterferon alfa-2b
1532:Peginterferon alfa-2a
1052:Asialo erythropoietin
582:Journal of Immunology
1488:Interferon alfacon-1
1117:Erythropoietin (EPO)
771:Autoimmunity Reviews
684:10.1084/jem.20041674
306:rheumatoid arthritis
292:BAFF is involved in
2061:Engineered proteins
1635:See IL-28R (IFNLR)
1603:Interferon gamma 1b
1493:Interferon alpha-n3
298:autoimmune diseases
265:Mechanism of action
257:as a treatment for
23:
1991:Oncostatin M (OSM)
1517:Interferon beta 1b
1512:Interferon beta 1a
1483:Interferon alfa n1
1478:Interferon alfa 2b
1473:Interferon alfa 2a
1307:Kinase inhibitors:
914:ClinicalTrials.gov
310:multiple sclerosis
2043:
2042:
2039:
2038:
1961:
1960:
1728:
1646:
1645:
1379:
1378:
1122:Erythropoietin-Fc
996:Cytokine receptor
813:(9767): 721–731.
498:10.1002/art.23678
236:
235:
16:Chemical compound
2068:
1732:
1722:
1715:
1574:Decoy receptors:
1390:
1067:Darbepoetin alfa
1032:
989:
982:
975:
966:
960:
959:
934:(9): 1667–1675.
922:
916:
904:
898:
897:
895:
894:
879:
873:
872:
870:
869:
845:
839:
838:
801:
795:
794:
766:
757:
756:
746:
736:
712:
706:
705:
695:
663:
657:
656:
638:
623:Modern Pathology
614:
608:
607:
597:
573:
564:
563:
553:
544:(6): 1313–1319.
529:
520:
519:
509:
492:(8): 2453–2459.
481:
475:
474:
438:
429:
428:
426:
424:
409:
400:
399:
397:
396:
381:
314:Sjögren syndrome
285:(Fc) of a human
269:Blisibimod is a
232:
231:
224:
213:
211:
194:
188:
182:
176:
170:
150:
130:
94:
24:
22:
2076:
2075:
2071:
2070:
2069:
2067:
2066:
2065:
2046:
2045:
2044:
2035:
1957:
1953:Deucravacitinib
1939:
1881:
1793:
1721:
1706:
1686:
1666:
1642:
1622:
1581:
1415:Interferon alfa
1375:
1334:
1314:
1263:
1197:
1193:Pegnartograstim
1178:Lipegfilgrastim
1141:
1087:Epoetin epsilon
1021:
1001:
993:
963:
924:
923:
919:
905:
901:
892:
890:
881:
880:
876:
867:
865:
847:
846:
842:
803:
802:
798:
768:
767:
760:
714:
713:
709:
665:
664:
660:
616:
615:
611:
575:
574:
567:
531:
530:
523:
483:
482:
478:
455:10.1038/nrd2085
440:
439:
432:
422:
420:
411:
410:
403:
394:
392:
383:
382:
371:
367:
359:IgA nephropathy
338:
318:Graves' disease
302:lupus nephritis
275:binding domains
267:
241:(also known as
227:
225:
222:(what is this?)
219:
209:
207:
197:
191:
185:
179:
173:
153:
133:
113:
97:
72:
69:Investigational
51:
17:
12:
11:
5:
2074:
2072:
2064:
2063:
2058:
2048:
2047:
2041:
2040:
2037:
2036:
2034:
2033:
2028:
2023:
2018:
2013:
2008:
1999:
1998:
1993:
1988:
1983:
1978:
1969:
1967:
1963:
1962:
1959:
1958:
1956:
1955:
1949:
1947:
1941:
1940:
1938:
1937:
1932:
1927:
1922:
1917:
1912:
1907:
1902:
1897:
1895:Cercosporamide
1891:
1889:
1883:
1882:
1880:
1879:
1874:
1869:
1864:
1859:
1854:
1849:
1844:
1839:
1837:Deuruxolitinib
1834:
1829:
1824:
1819:
1814:
1809:
1803:
1801:
1795:
1794:
1792:
1791:
1786:
1781:
1776:
1771:
1766:
1761:
1756:
1754:Deuruxolitinib
1751:
1746:
1740:
1738:
1729:
1712:
1708:
1707:
1705:
1704:
1696:
1694:
1688:
1687:
1685:
1684:
1676:
1674:
1668:
1667:
1665:
1664:
1656:
1654:
1648:
1647:
1644:
1643:
1641:
1640:
1632:
1630:
1628:IFNLR (λ, III)
1624:
1623:
1621:
1620:
1615:
1606:
1605:
1600:
1591:
1589:
1583:
1582:
1580:
1579:
1570:
1569:
1564:
1559:
1554:
1549:
1540:
1539:
1534:
1529:
1524:
1519:
1514:
1509:
1495:
1490:
1485:
1480:
1475:
1470:
1412:
1407:
1398:
1396:
1394:IFNAR (α/β, I)
1387:
1381:
1380:
1377:
1376:
1374:
1373:
1368:
1363:
1361:Promegapoietin
1358:
1353:
1344:
1342:
1340:Thrombopoietin
1336:
1335:
1333:
1332:
1324:
1322:
1316:
1315:
1313:
1312:
1303:
1302:
1297:
1292:
1287:
1285:Interleukin-34
1282:
1273:
1271:
1265:
1264:
1262:
1261:
1256:
1251:
1242:
1241:
1236:
1231:
1226:
1221:
1216:
1207:
1205:
1199:
1198:
1196:
1195:
1190:
1185:
1180:
1175:
1170:
1165:
1160:
1151:
1149:
1143:
1142:
1140:
1139:
1134:
1129:
1124:
1119:
1114:
1109:
1104:
1099:
1094:
1089:
1084:
1079:
1074:
1069:
1064:
1059:
1054:
1049:
1040:
1038:
1036:Erythropoietin
1029:
1023:
1022:
1020:
1019:
1011:
1009:
1003:
1002:
994:
992:
991:
984:
977:
969:
962:
961:
917:
899:
874:
840:
796:
777:(3): 165–169.
758:
707:
678:(2): 195–200.
658:
609:
565:
521:
476:
449:(7): 564–576.
430:
419:on 3 June 2011
401:
368:
366:
363:
337:
334:
271:fusion protein
266:
263:
234:
233:
216:
215:
205:
199:
198:
195:
189:
183:
177:
171:
166:
160:
159:
155:
154:
152:
151:
143:
141:
135:
134:
132:
131:
123:
121:
115:
114:
112:
111:
107:
105:
99:
98:
96:
95:
87:
85:
79:
78:
74:
73:
71:
70:
66:
64:
58:
57:
53:
52:
50:
49:
45:
43:
37:
36:
33:
29:
28:
15:
13:
10:
9:
6:
4:
3:
2:
2073:
2062:
2059:
2057:
2054:
2053:
2051:
2032:
2029:
2027:
2024:
2022:
2019:
2017:
2014:
2012:
2009:
2007:
2004:
2001:
2000:
1997:
1994:
1992:
1989:
1987:
1984:
1982:
1979:
1977:
1974:
1971:
1970:
1968:
1964:
1954:
1951:
1950:
1948:
1946:
1942:
1936:
1933:
1931:
1928:
1926:
1923:
1921:
1918:
1916:
1913:
1911:
1908:
1906:
1903:
1901:
1898:
1896:
1893:
1892:
1890:
1888:
1884:
1878:
1875:
1873:
1870:
1868:
1865:
1863:
1860:
1858:
1855:
1853:
1850:
1848:
1845:
1843:
1840:
1838:
1835:
1833:
1830:
1828:
1825:
1823:
1820:
1818:
1815:
1813:
1810:
1808:
1805:
1804:
1802:
1800:
1796:
1790:
1787:
1785:
1782:
1780:
1777:
1775:
1772:
1770:
1767:
1765:
1762:
1760:
1757:
1755:
1752:
1750:
1747:
1745:
1742:
1741:
1739:
1737:
1733:
1730:
1726:
1720:
1716:
1713:
1709:
1702:
1698:
1697:
1695:
1693:
1689:
1682:
1678:
1677:
1675:
1673:
1669:
1662:
1658:
1657:
1655:
1653:
1649:
1638:
1634:
1633:
1631:
1629:
1625:
1619:
1616:
1614:
1611:
1608:
1607:
1604:
1601:
1599:
1596:
1593:
1592:
1590:
1588:
1587:IFNGR (γ, II)
1584:
1578:
1575:
1572:
1571:
1568:
1565:
1563:
1560:
1558:
1555:
1553:
1550:
1548:
1545:
1542:
1541:
1538:
1535:
1533:
1530:
1528:
1525:
1523:
1520:
1518:
1515:
1513:
1510:
1507:
1503:
1499:
1496:
1494:
1491:
1489:
1486:
1484:
1481:
1479:
1476:
1474:
1471:
1468:
1464:
1460:
1456:
1452:
1448:
1444:
1440:
1436:
1432:
1428:
1424:
1420:
1416:
1413:
1411:
1408:
1406:
1405:Albinterferon
1403:
1400:
1399:
1397:
1395:
1391:
1388:
1386:
1382:
1372:
1369:
1367:
1364:
1362:
1359:
1357:
1354:
1352:
1349:
1346:
1345:
1343:
1341:
1337:
1330:
1326:
1325:
1323:
1321:
1317:
1311:
1308:
1305:
1304:
1301:
1298:
1296:
1293:
1291:
1288:
1286:
1283:
1281:
1278:
1275:
1274:
1272:
1270:
1266:
1260:
1257:
1255:
1252:
1250:
1247:
1244:
1243:
1240:
1237:
1235:
1232:
1230:
1227:
1225:
1222:
1220:
1217:
1215:
1212:
1209:
1208:
1206:
1204:
1203:GM-CSF (CSF2)
1200:
1194:
1191:
1189:
1188:Pegfilgrastim
1186:
1184:
1181:
1179:
1176:
1174:
1171:
1169:
1166:
1164:
1161:
1159:
1156:
1153:
1152:
1150:
1148:
1144:
1138:
1135:
1133:
1130:
1128:
1125:
1123:
1120:
1118:
1115:
1113:
1110:
1108:
1107:Epoetin theta
1105:
1103:
1102:Epoetin omega
1100:
1098:
1097:Epoetin kappa
1095:
1093:
1092:Epoetin gamma
1090:
1088:
1085:
1083:
1082:Epoetin delta
1080:
1078:
1075:
1073:
1070:
1068:
1065:
1063:
1060:
1058:
1055:
1053:
1050:
1048:
1045:
1042:
1041:
1039:
1037:
1033:
1030:
1028:
1024:
1017:
1013:
1012:
1010:
1008:
1004:
1000:
997:
990:
985:
983:
978:
976:
971:
970:
967:
957:
953:
949:
945:
941:
937:
933:
929:
921:
918:
915:
911:
910:
903:
900:
889:on 2012-03-27
888:
884:
878:
875:
864:on 2011-10-02
863:
859:
855:
851:
844:
841:
836:
832:
828:
824:
820:
816:
812:
808:
800:
797:
792:
788:
784:
780:
776:
772:
765:
763:
759:
754:
750:
745:
740:
735:
730:
726:
722:
718:
711:
708:
703:
699:
694:
689:
685:
681:
677:
673:
669:
662:
659:
654:
650:
646:
642:
637:
632:
629:(1): 98–107.
628:
624:
620:
613:
610:
605:
601:
596:
591:
587:
583:
579:
572:
570:
566:
561:
557:
552:
547:
543:
539:
535:
528:
526:
522:
517:
513:
508:
507:2027.42/60900
503:
499:
495:
491:
487:
480:
477:
472:
468:
464:
460:
456:
452:
448:
444:
437:
435:
431:
418:
414:
408:
406:
402:
391:on 2011-09-02
390:
386:
380:
378:
376:
374:
370:
364:
362:
360:
355:
351:
347:
343:
335:
333:
331:
327:
323:
319:
315:
311:
307:
303:
299:
295:
290:
288:
284:
280:
277:fused to the
276:
272:
264:
262:
260:
256:
252:
248:
244:
240:
230:
223:
217:
206:
204:
200:
167:
165:
161:
156:
149:
145:
144:
142:
140:
136:
129:
125:
124:
122:
120:
116:
109:
108:
106:
104:
100:
93:
89:
88:
86:
84:
80:
75:
68:
67:
65:
63:
59:
54:
47:
46:
44:
42:
38:
34:
30:
27:Clinical data
25:
2011:Lestaurtinib
2002:
1972:
1910:Ritlecitinib
1842:Lestaurtinib
1789:Upadacitinib
1618:Fontolizumab
1609:
1594:
1573:
1562:Rontalizumab
1543:
1401:
1356:Pegacaristim
1347:
1306:
1276:
1269:M-CSF (CSF1)
1249:Mavrilimumab
1245:
1239:Sargramostim
1229:Molgramostim
1214:Ecogramostim
1210:
1183:Nartograstim
1154:
1147:G-CSF (CSF3)
1132:Peginesatide
1112:Epoetin zeta
1077:Epoetin beta
1072:Epoetin alfa
1043:
931:
927:
920:
907:
902:
891:. Retrieved
887:the original
877:
866:. Retrieved
862:the original
857:
853:
843:
810:
806:
799:
774:
770:
724:
720:
710:
675:
671:
661:
626:
622:
612:
585:
581:
541:
537:
489:
485:
479:
446:
442:
421:. Retrieved
417:the original
393:. Retrieved
389:the original
339:
291:
268:
246:
242:
238:
237:
226:
220:
92:1236126-45-6
62:Legal status
56:Legal status
2021:Quizartinib
2016:Midostaurin
1905:Peficitinib
1867:Ruxolitinib
1862:Peficitinib
1817:Baricitinib
1779:Ruxolitinib
1774:Peficitinib
1769:Oclacitinib
1764:Momelotinib
1749:Baricitinib
1744:Abrocitinib
1652:Interleukin
1610:Antibodies:
1567:Sifalimumab
1552:Faralimomab
1547:Anifrolumab
1544:Antibodies:
1366:Romiplostim
1351:Eltrombopag
1320:SCF (c-Kit)
1246:Antibodies:
1234:Regramostim
1168:Lenograstim
909:NCT01162681
588:(1): 6–10.
336:Development
245:, formerly
214: g·mol
77:Identifiers
32:Other names
2050:Categories
2006:Emfilermin
1857:Pacritinib
1759:Filgotinib
1725:inhibitors
1613:Emapalumab
1385:Interferon
1310:Agerafenib
1300:Mirimostim
1290:Lanimostim
1224:Milodistim
1173:Leridistim
1158:Filgrastim
999:modulators
893:2011-07-15
868:2011-07-15
395:2011-07-08
365:References
279:N-terminus
239:Blisibimod
203:Molar mass
128:114VP6C6ES
103:ChemSpider
83:CAS Number
21:Blisibimod
2031:Sunitinib
2026:Sorafenib
1935:ZM-449829
1925:WHI-P 154
1915:TCS-21311
1852:NSC-33994
1807:Atiprimod
1595:Agonists:
1577:Bifarcept
1402:Agonists:
1348:Agonists:
1280:Cilmostim
1277:Agonists:
1254:Namilumab
1211:Agonists:
1155:Agonists:
1044:Agonists:
1007:Chemokine
727:: 38–43.
330:receptors
1930:ZM-39923
1847:NSC-7908
1812:AZD-1480
1703:instead.
1683:instead.
1663:instead.
1639:instead.
1557:MEDI-545
1331:instead.
1259:Otilimab
1062:CNTO-530
1018:instead.
956:23122293
948:24748629
835:28952240
827:21296403
791:19647102
753:19088870
702:15642740
653:11795623
645:20890272
604:11123269
560:11407690
516:18668552
463:16816838
354:Phase II
326:inhibits
287:antibody
229:(verify)
41:ATC code
1872:SD-1008
1047:ARA-290
744:2577948
693:2212784
471:9159761
423:15 July
350:placebo
346:Phase I
344:, with
281:of the
247:AMG 623
164:Formula
1966:Others
1832:CYT387
1822:CHZ868
1711:Others
1467:IFNA21
1463:IFNA17
1459:IFNA16
1455:IFNA14
1451:IFNA13
1447:IFNA10
954:
946:
833:
825:
807:Lancet
789:
751:
741:
700:
690:
651:
643:
602:
558:
514:
469:
461:
320:, and
294:B-cell
148:D10311
1506:IFNB3
1502:IFNB1
1443:IFNA8
1439:IFNA7
1435:IFNA6
1431:IFNA5
1427:IFNA4
1423:IFNA2
1419:IFNA1
952:S2CID
831:S2CID
649:S2CID
467:S2CID
342:Amgen
243:A-623
35:A-623
1945:TYK2
1887:JAK3
1799:JAK2
1736:JAK1
1701:here
1699:See
1681:here
1679:See
1672:TGFβ
1661:here
1659:See
1637:here
1329:here
1327:See
1016:here
1014:See
944:PMID
823:PMID
787:PMID
749:PMID
698:PMID
641:PMID
600:PMID
556:PMID
512:PMID
459:PMID
425:2011
178:4376
172:2836
139:KEGG
119:UNII
110:none
48:none
1719:JAK
1692:TNF
1027:CSF
936:doi
815:doi
811:377
779:doi
739:PMC
729:doi
688:PMC
680:doi
676:201
631:doi
590:doi
586:166
546:doi
502:hdl
494:doi
451:doi
212:.20
210:624
190:858
184:756
2052::
1504:,
1465:,
1461:,
1457:,
1453:,
1449:,
1445:,
1441:,
1437:,
1433:,
1429:,
1425:,
1421:,
950:.
942:.
932:74
930:.
858:69
856:.
852:.
829:.
821:.
809:.
785:.
773:.
761:^
747:.
737:.
723:.
719:.
696:.
686:.
674:.
670:.
647:.
639:.
627:24
625:.
621:.
598:.
584:.
580:.
568:^
554:.
542:44
540:.
536:.
524:^
510:.
500:.
490:58
488:.
465:.
457:.
445:.
433:^
404:^
372:^
361:.
316:,
312:,
308:,
304:,
289:.
208:63
196:26
1727:)
1723:(
1508:)
1500:(
1469:)
1417:(
988:e
981:t
974:v
958:.
938::
896:.
871:.
837:.
817::
793:.
781::
775:9
755:.
731::
725:2
704:.
682::
655:.
633::
606:.
592::
562:.
548::
518:.
504::
496::
473:.
453::
447:5
427:.
398:.
193:S
187:O
181:N
175:H
169:C
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.